Modality
Multispecific
MOA
IL-23i
Target
BET
Pathway
Complement
DMDMDD
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
~Nov 2018
→ ~Feb 2020
Phase 3
May 2020
→ Apr 2030
Phase 3Current
NCT08300190
1,564 pts·MDD
2020-05→2030-04·Recruiting
1,564 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-124.0y awayPh3 Readout· MDD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Recruit…
Catalysts
Ph3 Readout
2030-04-12 · 4.0y away
MDD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08300190 | Phase 3 | MDD | Recruiting | 1564 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| 207-5197 | Samsung Biologics | Approved | BET |